CN116390714A - 局部眼科组合物 - Google Patents

局部眼科组合物 Download PDF

Info

Publication number
CN116390714A
CN116390714A CN202180068863.0A CN202180068863A CN116390714A CN 116390714 A CN116390714 A CN 116390714A CN 202180068863 A CN202180068863 A CN 202180068863A CN 116390714 A CN116390714 A CN 116390714A
Authority
CN
China
Prior art keywords
ophthalmic composition
topical ophthalmic
atropine
eye
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068863.0A
Other languages
English (en)
Chinese (zh)
Inventor
倪劲松
杨嵘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ads Medical Co ltd
Original Assignee
Ads Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ads Medical Co ltd filed Critical Ads Medical Co ltd
Publication of CN116390714A publication Critical patent/CN116390714A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180068863.0A 2020-10-08 2021-10-08 局部眼科组合物 Pending CN116390714A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063089263P 2020-10-08 2020-10-08
US63/089,263 2020-10-08
US17/317,551 2021-05-11
US17/317,551 US11191751B1 (en) 2020-10-08 2021-05-11 Topical ophthalmological atropine free base compositions
PCT/US2021/054221 WO2022076852A1 (en) 2020-10-08 2021-10-08 Topical ophthalmological compositions

Publications (1)

Publication Number Publication Date
CN116390714A true CN116390714A (zh) 2023-07-04

Family

ID=78818588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068863.0A Pending CN116390714A (zh) 2020-10-08 2021-10-08 局部眼科组合物

Country Status (11)

Country Link
US (2) US11191751B1 (https=)
EP (2) EP4225284B1 (https=)
JP (1) JP2023544853A (https=)
KR (1) KR20230084190A (https=)
CN (1) CN116390714A (https=)
AU (1) AU2021359003A1 (https=)
BR (1) BR112023006371A2 (https=)
CA (1) CA3193940A1 (https=)
ES (1) ES3063371T3 (https=)
MX (1) MX2023004065A (https=)
WO (1) WO2022076852A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
MX2023009091A (es) 2021-02-03 2023-08-09 Ads Therapeutics Llc Composiciones oftalmologicas topicas.
KR20240136369A (ko) * 2022-01-21 2024-09-13 에이디에스 테라퓨틱스 엘엘씨 8-메틸-8-아자비사이클로[3.2.1] 옥탄-3-일의 에스테르 3-하이드록시-2-페닐프로파노에이트
JP2025541009A (ja) 2022-12-23 2025-12-17 ノバリック ゲーエムベーハー ヒヨスチアミンを含む半フッ化アルカン組成物
CN117982412B (zh) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 一种醋克利定眼用组合物及其药物制剂和用途
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025264886A1 (en) * 2024-06-19 2025-12-26 Btv Holding, Llc Ophthalmic preparations and methods of use
WO2026011139A1 (en) * 2024-07-05 2026-01-08 Ads Therapeutics Llc Transient receptor potential melastatin 8 agonist-containing ocular conditions and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102652022A (zh) * 2009-12-14 2012-08-29 诺瓦利克有限责任公司 治疗干眼综合征的药物组合物
WO2019084621A1 (en) * 2017-11-03 2019-05-09 Brien Holden Vision Institute Pharmaceutical compositions for controlling and/or reducing the progression of myopia
CN110248657A (zh) * 2016-12-22 2019-09-17 诺瓦利克有限责任公司 用于治疗眼内炎性眼病的包含他克莫司的组合物
WO2020074697A1 (en) * 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020160493A2 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
CN113679699B (zh) * 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11510931B2 (en) * 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
WO2019068763A1 (en) * 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
WO2020152046A1 (en) * 2019-01-21 2020-07-30 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
MX2023009091A (es) * 2021-02-03 2023-08-09 Ads Therapeutics Llc Composiciones oftalmologicas topicas.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102652022A (zh) * 2009-12-14 2012-08-29 诺瓦利克有限责任公司 治疗干眼综合征的药物组合物
CN110248657A (zh) * 2016-12-22 2019-09-17 诺瓦利克有限责任公司 用于治疗眼内炎性眼病的包含他克莫司的组合物
WO2019084621A1 (en) * 2017-11-03 2019-05-09 Brien Holden Vision Institute Pharmaceutical compositions for controlling and/or reducing the progression of myopia
WO2020074697A1 (en) * 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020160493A2 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R.M, DUTESCU等: "Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 88, no. 1, 30 September 2014 (2014-09-30), pages 123 - 128, XP029053290, DOI: 10.1016/j.ejpb.2014.05.009 *
S. DE MAJUMDAR等: "A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA) Eyedrop Suppresses Intraocular Inflammation in Experimental Models of Uveitis", CURRENT MOLECULAR MEDICINE, vol. 17, no. 3, 1 March 2017 (2017-03-01), pages 211 - 220 *

Also Published As

Publication number Publication date
US20230355594A1 (en) 2023-11-09
EP4706766A2 (en) 2026-03-11
CA3193940A1 (en) 2022-04-14
EP4225284B1 (en) 2025-11-26
WO2022076852A1 (en) 2022-04-14
AU2021359003A1 (en) 2023-05-04
ES3063371T3 (en) 2026-04-16
US11191751B1 (en) 2021-12-07
EP4225284C0 (en) 2025-11-26
KR20230084190A (ko) 2023-06-12
BR112023006371A2 (pt) 2023-05-09
JP2023544853A (ja) 2023-10-25
EP4225284A1 (en) 2023-08-16
MX2023004065A (es) 2023-05-03
AU2021359003A9 (en) 2024-06-13
EP4225284A4 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
CN116390714A (zh) 局部眼科组合物
US12485177B2 (en) Topical ophthalmological compositions
AU2023203933B2 (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
US20110294897A1 (en) Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
WO2021017475A1 (zh) 一种含有环孢素的眼用药物组合物、其制备方法及用途
AU2023203716A1 (en) Methods for treating ocular surface pain
HK40086649A (zh) 局部眼科组合物
US20260124305A1 (en) Topical ophthalmological compositions
CN120093684A (zh) 局部眼科组合物
CN117982412B (zh) 一种醋克利定眼用组合物及其药物制剂和用途
CN115531302B (zh) 一种用于制备治疗角膜血管新生病症的眼用组合物
RU2850452C2 (ru) Способы лечения боли на поверхности глаза
HK40126394A (zh) 一种α-肾上腺素受体激动剂眼用组合物及其用途
WO2026018131A1 (en) Ocular compositions
WO2022105720A1 (zh) 一种格列本脲的药物组合物及其制备方法
CN101199515A (zh) 盐酸苄达明洗剂及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40086649

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination